Understand the source comparison
503B Facility Requirements vs 503A Patient-Specific Compounding
| Facility Type | Registration Requirement | Interstate Distribution | Bulk Drug Substance Use | Inspection Frequency | Commercial Scale Allowed | Professional Assessment ||—|—|—|—|—|—|| 503A Compounding Pharmacy | State pharmacy board license only | Prohibite
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Facility Type | Registration Requirement | Interstate Distribution | Bulk Drug Substance Use | Inspection Frequency | Commercial Scale Allowed | Professional Assessment ||—|—|—|—|—|—|| 503A Compounding Pharmacy | State pharmacy board license only | Prohibited (up to 5% of total prescriptions per federal exemption) | Prohibited unless substance appears on FDA's approved list | State-determined (typically every 2–3 years) | No—patient-specific only | Best for truly individualised formulations where dose, excipients, or delivery method must be customised per patient—not appropriate for standardised weight-loss protocols || 503B Outsourcing Facility | FDA registration + state license | Permitted across all 50 states | Permitted if substance is nominated or approved | FDA inspects annually (risk-based schedule) | Yes—can produce batches without patient-specific prescriptions | Required for any commercial peptide program—the only pathway that allows interstate distribution and bulk manufac
- The FDA treats 503B facilities as drug manufacturers subject to Current Good Manufacturing Practice (CGMP) standards, while 503A pharmacies operate under less stringent state compounding rules. That distinction determines whether peptides can be compounded legally at the scale most telehealth and weight management clinics require. If your practice dispenses pre-filled syringes or vials prepared in batches, you're relying on a 503B facility whether you realise it or not—503A operations can't produce inventory before receiving individual prescriptions.
- Here's what most prescribers miss: the peptide compounding regulations 2026 doctors face don't prohibit compounding from bulk drug substances if the facility is registered correctly and the substance is nominated. The issue is that many practices unknowingly partner with pharmacies operating outside their authorised scope, creating liability when enforcement actions occur. Before writing another prescription, verify: (1) Does the pharmacy hold active 503B registration searchable on the FDA's public database? (2) Has the bulk drug substance you're prescribing been nominated, and is it under active FDA review? (3) Does your state require additional prescriber documentation beyond the prescription itself?